Open AccessInhaled mannitol as a new mucolytic for treatment of cystic fibrosis
Author(s) -
Ю. В. Горинова,
С. А. Красовский,
O. Simonova,
E. Amelina
Publication year - 2017
Publication title -
pulʹmonologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 6
eISSN - 2541-9617
pISSN - 0869-0189
DOI - 10.18093/0869-0189-2016-26-6-760-765
Subject(s) - medicine , sputum , cystic fibrosis , intensive care medicine , clinical trial , population , pathology , environmental health , tuberculosis
Mucolytics with efficacy approved for cystic fibrosis (CF) have been reviewed by the authors. Currently, investigators search for new mucoactive agents to improve sputum rheology and expectoration in CF. One the promising mucolytics is inhaled dry powder mannitol which was effective and safe in several international trials. Inhaled mannitol has been implemented in clinical practice for CF treatment in some countries. Therefore, goals of new studies should be optimization the use, determination the target population and investigation of combined therapy with different mucolytics in CF.